Organogenesis Holdings stock (US68620V1026): shares react to earnings and outlook update

Organogenesis Holdings shares have been active after the regenerative medicine company reported quarterly results and updated its 2024 outlook, prompting fresh attention from US healthcare investors.

Organogenesis Holdings shares have seen increased trading interest after the regenerative medicine company reported its latest quarterly results and provided an updated outlook for 2024, highlighting trends in its advanced wound care and surgical products businesses, according to a company earnings release published on 05/08/2024 and subsequent coverage from financial media on the same dateOrganogenesis investor relations as of 05/08/2024Reuters as of 05/08/2024.

As of: 05/14/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Organogenesis Holdings Inc.
• Sector/industry: Regenerative medicine, medical devices, advanced wound care
• Headquarters/country: Canton, Massachusetts, United States
• Core markets: United States hospital, outpatient wound care centers, and physician office markets
• Key revenue drivers: Advanced wound care products and surgical biologics for tissue repair
• Home exchange/listing venue: Nasdaq Global Select Market (ticker: ORGO)
• Trading currency: US dollar (USD)

Organogenesis Holdings: core business model

Organogenesis Holdings focuses on regenerative medicine products designed to support the healing of complex wounds, such as diabetic foot ulcers and venous leg ulcers, and to assist in tissue repair in surgical settings, according to its corporate profile and product descriptions as of 03/27/2024Organogenesis company information as of 03/27/2024.

The company operates primarily in two reporting segments: Advanced Wound Care, which includes bioengineered skin substitutes and related wound treatments, and Surgical & Sports Medicine, which offers regenerative tissue products for orthopedic and spine procedures, as outlined in its 2023 annual report and Form 10-K filed on 03/13/2024Organogenesis Form 10-K as of 03/13/2024.

Revenue is generated largely through sales to hospitals, outpatient wound care centers, and physician practices, with a significant portion of demand influenced by reimbursement policies from Medicare, Medicaid, and commercial insurers in the United States, as highlighted in the company’s risk factor disclosures in its 2023 Form 10-K filed on 03/13/2024Organogenesis Form 10-K as of 03/13/2024.

Main revenue and product drivers for Organogenesis Holdings

In its first-quarter 2024 earnings release, Organogenesis reported net revenue of approximately 108 million USD for the quarter ended 03/31/2024, compared with around 107 million USD in the prior-year period, reflecting modest year-over-year growth driven mainly by its advanced wound care portfolioOrganogenesis investor relations as of 05/08/2024.

The company noted that sales of key advanced wound care products grew in the low- to mid-single-digit percentage range compared with the first quarter of 2023, supported by stable procedure volumes and continued adoption in outpatient wound centers, according to its 05/08/2024 earnings statement and accompanying commentaryOrganogenesis investor presentation as of 05/08/2024.

By contrast, the Surgical & Sports Medicine segment remained a smaller contributor to overall revenue, but management emphasized its longer-term potential as more surgeons adopt biologic implants for soft tissue reinforcement and cartilage repair, based on remarks in the company’s 05/08/2024 earnings call transcript summarized by financial news outletsSeeking Alpha transcript summary as of 05/08/2024.

Gross margin for the quarter ended 03/31/2024 was reported to be in the mid-70 percent range, reflecting the high-value nature of the company’s biologic products but also ongoing cost pressures related to manufacturing and reimbursement dynamics, according to the Q1 2024 release dated 05/08/2024Organogenesis investor relations as of 05/08/2024.

Adjusted EBITDA for the first quarter of 2024 was reported at a positive level, indicating continued profitability on an adjusted basis, while net income under generally accepted accounting principles remained modest due to research and development spending and other operating expenses, as specified in the detailed financial tables accompanying the 05/08/2024 earnings press releaseOrganogenesis earnings tables as of 05/08/2024.

Management reaffirmed its full-year 2024 revenue guidance range in the low- to mid-single-digit percentage growth area versus 2023, pointing to the resilience of advanced wound care demand and expectations for gradual improvement in surgical volumes, according to guidance commentary included in the 05/08/2024 Q1 2024 releaseOrganogenesis guidance details as of 05/08/2024.

For 2023, the company reported annual net revenue of approximately 442 million USD, down from around 450 million USD in 2022, primarily due to changes in Medicare reimbursement for certain wound care products, according to its annual report and press release dated 03/13/2024 covering the year ended 12/31/2023Organogenesis full-year 2023 results as of 03/13/2024.

Despite the modest decline in 2023 revenue, the company highlighted that unit volumes for several flagship products continued to grow, with the revenue impact largely attributable to reimbursement adjustments rather than underlying demand, based on commentary contained in the 03/13/2024 full-year 2023 results release and conference call summaryFierce Biotech as of 03/14/2024.

The company’s pipeline includes next-generation regenerative medicine products for advanced wounds and surgical indications, with several programs in various stages of clinical and preclinical development, according to its research and development overview section in the 2023 Form 10-K filed on 03/13/2024Organogenesis Form 10-K as of 03/13/2024.

Why Organogenesis Holdings matters for US investors

Organogenesis is directly tied to the US healthcare system because most of its sales are generated in the United States and reimbursed by Medicare, Medicaid, and private payers, making policy and coding decisions in Washington and from the Centers for Medicare & Medicaid Services important drivers of financial performance, as emphasized in the reimbursement risk discussion in the 2023 Form 10-K filed on 03/13/2024Organogenesis Form 10-K as of 03/13/2024.

For US investors, the company also offers exposure to the broader trend of rising incidence of chronic wounds associated with diabetes and an aging population, with clinical and economic data referenced in the company’s investor materials indicating a sizable addressable market for advanced wound care therapies, as described in an investor presentation dated 03/27/2024Organogenesis investor presentation as of 03/27/2024.

Because the shares trade on Nasdaq under the ticker ORGO, Organogenesis is accessible to a wide range of US retail investors via standard brokerage platforms, and the stock can be influenced by broader movements in US small- and mid-cap healthcare and medtech indices, according to index composition information from Nasdaq and sector commentary from financial media as of 04/12/2024Nasdaq stock overview as of 04/12/2024.

Conclusion

Organogenesis Holdings sits at the intersection of regenerative medicine, advanced wound care, and US healthcare reimbursement trends, with its latest quarterly results showing modest revenue growth and continued profitability on an adjusted basis amid ongoing pricing and policy headwinds. The company’s focus on advanced wound care and surgical biologics provides exposure to markets influenced by demographic shifts and the increasing prevalence of chronic conditions, while also leaving performance sensitive to reimbursement changes and clinical adoption. For US investors following the healthcare and medical technology space, Organogenesis represents a specialized player whose prospects depend on execution in its core product lines, regulatory and reimbursement stability, and the success of its innovation pipeline over the coming years.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.